Roel Verhaak

Same. Squirrels here have learned to shake the birdfeeder so the contents spill, meaning to only have to leap jump once every time we fill it up. They are smart creatures.

Plot of modeling new NIH grants after a switch to 100% MYF. There is a large drop in grants in the first year with a gradual recovery over 5 years.

There is a lot of talk lately about multi-year funding (MYF) at NIH. This is mostly a paperwork issue, but it can have a dramatic impact on the number of grants that get funded. I was curious how this would impact grant numbers over time, so I did some simple modeling. 1/n

Raise your hand if you think that the new biosketch formatting will improve the ways NIH distributes extramural funding or funding transparency.

Having too much with the new wired birdfeeder and its AI powered bird recognition feature. Its a dark-eyed junco!

I can't believe this still needs to be said (and more loudly):

Trans rights are human rights.

And here is your accompanying editorial: Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development url: academic.oup.com/neuro-oncolo...

Happy to share a new #NORLUX study on how humanized patient-derived xenografts of #glioblastoma can be useful in investigating immunosuppression and clinically-relevant immunotherapy testing. See for more: www.biorxiv.org/content/10.1...
#immunotherapy, #preclinicalmodeling,

It was a great pleasure to learn about a recent discovery in ecDNA biology that answers the most critical question on ecDNA maintenance! @nature.com Are you a non-scientist? No worries! My team wrote a lay-audience-friendly summary about this exciting research finding! Check it out! rdcu.be/eQMvM

Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social

Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma AbstractBackground. Outcomes for adult patients with high-grade glioma (HGG) remain poor, necessitating new treatment strategies. Key challenges include po

Delighted to share this new collaborative paper with the Ivy BTC where we performed deep characterization of glioma patients enrolled on a CDK4/6i Phase 0 trial academic.oup.com/neuro-oncolo... with @kevin-johnson.bsky.social @shwetalm.bsky.social @nadersanai.bsky.social

Sharks absolutely get cancer, and people claiming otherwise are pseudoscientific grifters preying on the desperate.

Even if sharks did not get cancer, eating shark would not cure your cancer any more than eating LeBron James would make you better at basketball.

Senior Research Tech (Duke) – tumor immunobiology lab. Work with tumor/blood/CSF samples, culture patient-derived cell lines, assist single-cell assays, and support & lead research. Bio degree + research exp required. No visa sponsorship. Title may vary.
Apply → careers.duke.edu/job-invite/2...

Broad-Bayer collaboration leads to drug candidate for a hard-to-treat type of lung cancer The compound, now under priority review at FDA, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.

A new drug candidate for a difficult-to-treat type of lung cancer, developed by scientists in the Broad-Bayer oncology research alliance, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.

The immunology of brain tumors The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.

The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...

Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

Today’s lab meeting is a debate of recent Nature/Science retraction decisions: fair or not? Important lesson that not all retractions are the same, authors not always to blame.

Phenomenal work, Dan! Read it with pleasure.

Almost half way to our fundraising target - and only two weeks to go!

I'll be riding the 100 mile #CloserToFreeRide to raise money to support cancer research and patient care. Please consider donating - every penny counts!

➡️ www.rideclosertofree.org/participants...

#CTFRide @ctfride.bsky.social

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions Abstract. Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Orga

🔥 Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

Findings from @roelverhaak.bsky.social et al. reveal lentiviral transduction + antibiotic selection dramatically ⬇️ ecDNA+ #cancer cells, revealing both a challenge for research and a potential therapeutic clue. #ecdna
aacrjournals.org/cancerrescom...
@aacrjournals.bsky.social

Happy to provide a comment on recent work by the Maciejowski lab on ecDNA inheritance www.cell.com/molecular-ce... and authors.elsevier.com/a/1lZPK3vVUP... - with Xue Jin

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...

Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG

I took it for a small tortoiseshell (or its California version tortoiseshell) :) in that case, lady it is.

Could be male

You might want to check the grant status in Commons.

As individual PI, that may just set you up for further targeting.

Apparently payline was adjusted to 4th percentile for the May council. Unrelated to the budget of the grant.

PO just confirmed that our 5th percentile R01 is not getting funded. Past NCI Payline at 4 percent. Cant believe it.

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...

Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas Astrocytomas and oligodendrogliomas are slow-growing and treatment-sensitive IDH-mutant gliomas diagnosed at ages 30-50. Local tumor regrowth and treatment resistance is inevitable resulting in 3-10 y...

New preprint on longitudinal treatment response signatures in IDH-mutant glioma from the GLASS Consortium www.biorxiv.org/content/10.1...